Marketing reports, industrial technology reports and strategy reports, industrial research reports

Laser and optical parts maker II-VI said it would buy Apple supplier Finisar for about $3.2 billion, to grab a bigger slice of 5G investments and sell more sensors for iPhones and driverless cars. II-VI will pay Finisar shareholders $26 per share, in cash and stock, a premium of 37.7 percent to Finisar’s closing share price.

One of the world’s largest outsourced assembly and test providers names AP300E™ their preferred lithography system due to Veeco’s industry-leading uptime and process performance - Veeco Instruments announced that one of the world’s largest outsourced assembly and test (OSAT) providers has purchased multiple Veeco AP300E lithography systems.

Enables 5G equipment to be deployed anywhere, in any environment: solves critical timing challenges for 5G infrastructure - sets new performance benchmarks – 20 times better – in the $1.5 billion telecom and networking timing market - Unprecedented ease-of-use and programmability reduces design complexity and accelerates time to revenue.

Megatrend markets are pushing More than Moore (MtM) devices to new levels of complexity, resulting in big investments. In fact, the total equipment market for permanent bonding, lithography, and temporary bonding & debonding processes generated revenue of more than >$450M in 2017. This number is expected to reach >$850M by 2023, with a 10% compound annual growth rate (CAGR) over this period.

An article written by Mark Lapedus for Semiconductor Engineering - Cost and the lack of a panel-size standard gives fan-out a slower start. After years of R&D, panel-level fan-out packaging is finally beginning to ramp up in the market, at least in limited volumes for a few vendors.

With the number of cancer cases rising worldwide, there’s a critical need for better tools to diagnose and monitor treatment and recurrence. Every cancer is unique and involves various mutations of several genes. The more we know about the biology of cancer mutations, the better we can implement personalized treatments for patients. Usually, tissue biopsies are performed to obtain a sample of the tumor and analyze it. However, tissue biopsies are invasive and not easily repeatable - thus, they only provide a snapshot of the disease. To complement tissue biopsies, new tools are in development which involve less invasive procedures called liquid biopsy. This involves harvesting and analyzing rare biomarkers that are shed from tumors and circulate in the bloodstream, providing great insight into the disease.